EGFR and breast carcinoma: Ingenuity Pathway Analysis of RPPA data from control and osimertinib-treated GSC D317 revealed a blockade of several signaling pathways, including neuregulin, ErbB, HER2 signaling in breast cancer, and p70S6K signaling (Figure 2C).